Hologic (HOLX) Stock Forecast & Price Target

$79.81

-0.11 (-0.14%)

(As of 05:19 PM ET)

Hologic - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 13 Analyst Ratings

Sell
0

Hold
5

Buy
8

Based on 13 Wall Street analysts who have issued ratings for Hologic in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 13 analysts, 5 have given a hold rating, and 8 have given a buy rating for HOLX.

Consensus Price Target

$87.50
9.64% Upside

According to the 13 analysts' twelve-month price targets for Hologic, the average price target is $87.50. The highest price target for HOLX is $95.00, while the lowest price target for HOLX is $79.00. The average price target represents a forecasted upside of 9.64% from the current price of $79.81.

Get the Latest News and Ratings for HOLX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Hologic and its competitors.

HOLX Analyst Ratings Over Time

Type	Current Forecast 10/12/23 to 10/11/24	1 Month Ago 9/12/23 to 9/11/24	3 Months Ago 7/14/23 to 7/13/24	1 Year Ago 10/12/22 to 10/12/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	8 Buy rating(s)	7 Buy rating(s)	7 Buy rating(s)	8 Buy rating(s)
Hold	5 Hold rating(s)	4 Hold rating(s)	5 Hold rating(s)	6 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$87.50	$87.60	$85.55	$88.38
Forecasted Upside	9.64% Upside	9.49% Upside	10.11% Upside	30.17% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

Unveiled: NVIDIA’s "Secret Royalty" Program (Ad)

Did you know that there's an investment that will give you the opportunity to collect "royalties" every time Nvidia makes a chip?

Click Here to learn how to get in now >>>

HOLX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

HOLX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Hologic Stock vs. The Competition

Type	Hologic	Medical Companies	S&P 500
Consensus Rating Score	2.62	2.79	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	9.46% Upside	10,407.40% Upside	6.77% Upside
News Sentiment Rating	Neutral News See Recent HOLX News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
10/8/2024	Leerink Partners 1 of 5 stars		Lower Target	Outperform ➝ Outperform	$95.00 ➝ $90.00	+12.67%
10/4/2024	Mizuho 2 of 5 stars		Boost Target	Outperform ➝ Outperform	$85.00 ➝ $90.00	+12.80%
10/1/2024	Evercore ISI 2 of 5 stars		Boost Target	In-Line ➝ In-Line	$78.00 ➝ $82.00	+1.61%
10/1/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	P. Donnelly Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$95.00 ➝ $85.00	+4.35%
9/17/2024	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$90.00 ➝ $90.00	+8.83%
8/16/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Sector Perform ➝ Sector Perform	$82.00 ➝ $82.00	+1.22%
Get the Latest News and Ratings for HOLX and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Hologic and its competitors with MarketBeat's FREE daily newsletter.
7/30/2024	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Carrico Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$92.00 ➝ $92.00	+12.81%
7/30/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$91.00 ➝ $95.00	+24.67%
5/9/2024	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Toung Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$89.00 ➝ $95.00	+24.48%
2/2/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$78.00 ➝ $79.00	+9.27%
2/2/2024	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform
2/2/2024	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$85.00 ➝ $88.00	+21.30%
11/13/2023	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Equal Weight ➝ Equal Weight	$86.00 ➝ $82.00	+14.22%
8/1/2023	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$94.00 ➝ $86.00	+8.29%
2/2/2023	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform	$86.00 ➝ $95.00	+14.76%
1/10/2023	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight	$75.00 ➝ $80.00	+0.26%
11/1/2022	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform	$88.00 ➝ $86.00	+26.84%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 05:39 PM ET.

Should I Buy Hologic Stock? HOLX Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, October 7, 2024. Please send any questions or comments about these Hologic pros and cons to contact@marketbeat.com.

Hologic
Bull Case

Here are some ways that investors could benefit from investing in Hologic, Inc.:

Hologic, Inc. reported earnings per share of $1.06 for the last quarter, exceeding analysts' expectations by $0.04. This indicates strong financial performance and potential growth.
Institutional investors have been increasing their stakes in Hologic, Inc., with notable additions from various firms, signaling confidence in the company's future prospects.
The company's revenue for the last quarter was $1.01 billion, slightly surpassing analysts' estimates. This demonstrates consistent revenue generation and market stability.
Hologic, Inc. has a diverse product portfolio across diagnostics, medical imaging, and surgical products for women's health, providing a broad revenue stream and market presence.
The stock price of Hologic, Inc. has shown a positive trend, with a 50-day simple moving average of $80.20 and a 200-day simple moving average of $76.83, indicating potential price appreciation.

Hologic
Bear Case

Investors should be bearish about investing in Hologic, Inc. for these reasons:

Corporate insiders have recently sold 18,280 shares of Hologic, Inc. stock valued at $1,469,973 in the last three months, which may raise concerns about insider sentiment towards the company.
Hologic, Inc. has a PE ratio of 41.40, which is relatively high compared to industry averages, suggesting the stock may be overvalued based on earnings.
The company's price-to-earnings-growth ratio of 2.53 indicates that investors are paying a premium for the expected growth of the company, which could lead to increased risk.
Hologic, Inc. has a beta of 0.98, implying that the stock's price is less volatile compared to the overall market, potentially limiting short-term trading opportunities for investors.
While the company has shown revenue growth, the net margin of 17.59% may be considered moderate, indicating potential challenges in maintaining profitability amidst competition and market dynamics.

HOLX Forecast - Frequently Asked Questions

: According to the research reports of 13 Wall Street equities research analysts, the average twelve-month stock price forecast for Hologic is $87.50, with a high forecast of $95.00 and a low forecast of $79.00.
: 13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hologic in the last twelve months. There are currently 5 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" HOLX shares.
: According to analysts, Hologic's stock has a predicted upside of 9.64% based on their 12-month stock forecasts.
: Over the previous 90 days, Hologic's stock had 1 downgrade by analysts.
: Hologic has been rated by research analysts at Citigroup, Evercore ISI, JPMorgan Chase & Co., Leerink Partners, Mizuho, Needham & Company LLC, Royal Bank of Canada, and Stephens in the past 90 days.
: Analysts like Hologic less than other "medical" companies. The consensus rating score for Hologic is 2.62 while the average consensus rating score for "medical" companies is 2.79. Learn more on how HOLX compares to other companies.